SEC Form 4 filed by Director Webb Carol

$CTXR
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $CTXR alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Webb Carol

(Last) (First) (Middle)
C/O CITIUS PHARMACEUTICALS, INC.
11 COMMERCE DRIVE, 1ST FLOOR

(Street)
CRANFORD NJ 07016

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Citius Pharmaceuticals, Inc. [ CTXR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/07/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11,835 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Purchase Common Stock) $0.38 11/07/2024 A 125,000 (1) 11/07/2034 Common Stock 125,000 $0 125,000 D
Stock Option (Right to Purchase Common Stock) $0.7 (2) 10/10/2033 Common Stock 75,000 75,000 D
Stock Option (Right to Purchase Common Stock) $1.25 (2) 10/04/2032 Common Stock 75,000 75,000 D
Stock Option (Right to Purchase Common Stock) $2.04 (2) 10/11/2031 Common Stock 75,000 75,000 D
Stock Option (Right to Purchase Common Stock) $2 (2) 07/22/2031 Common Stock 15,000 15,000 D
Stock Option (Right to Purchase Common Stock) $1.69 (2) 02/16/2031 Common Stock 25,000 25,000 D
Stock Option (Right to Purchase Common Stock) $1.01 (2) 10/06/2030 Common Stock 35,000 35,000 D
Stock Option (Right to Purchase Common Stock) $1.39 (2) 07/07/2030 Common Stock 25,000 25,000 D
Stock Option (Right to Purchase Common Stock) $0.67 (2) 10/08/2029 Common Stock 25,000 25,000 D
Stock Option (Right to Purchase Common Stock) $1.62 (2) 09/04/2028 Common Stock 15,000 15,000 D
Stock Option (Right to Purchase Common Stock) $3.45 (2) 09/13/2027 Common Stock 10,000 10,000 D
Stock Option (Right to Purchase Common Stock) $12 (2) 06/23/2026 Common Stock 13,334 13,334 D
Explanation of Responses:
1. The options were granted on November 7, 2024. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date.
2. The options are vested in full and exercisable immediately.
/s/ Alexander M. Donaldson, by power of attorney 11/12/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $CTXR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CTXR

DatePrice TargetRatingAnalyst
12/30/2024$9.00Hold → Buy
D. Boral Capital
1/18/2022$4.00 → $6.00Buy
HC Wainwright & Co.
11/30/2021$4.00Buy
Maxim Group
More analyst ratings

$CTXR
Press Releases

Fastest customizable press release news feed in the world

See more
  • Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

    CRANFORD, N.J., Feb. 14, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter ended December 31, 2024. Fiscal First Quarter 2025 Business Highlights and Subsequent Developments Substantially advanced operational readiness for commercial launch of LYMPHIR in the first half of 2025;Secured a new permanent J-code, J9161, (Injection, denileukin diftitox-cxdl, for intravenous use, 1 microgram) for LYMPHIR™, assigned by the Centers for Medicare & Medicaid Serv

    $CTOR
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

    Permanent J-Code (J9161) expected to be effective April 1, 2025 LYMPHIR is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. CRANFORD, N.J., Feb. 6, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), today announced that LYMPHIR™ (denileukin diftitox-cxdl) has been assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code (J9161) by the Centers for Medicare & Medicaid

    $CTOR
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

    CRANFORD, N.J., Jan. 8, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (NASDAQ:CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive agreements for the purchase of an aggregate of 743,496 shares of its common stock and accompanying warrants to purchase up to an aggregate of 743,496 shares of its common stock, at a purchase price of $4.035 per share and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $3.91 per share, will be exercisable immedia

    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CTXR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CTXR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CTXR
SEC Filings

See more

$CTXR
Leadership Updates

Live Leadership Updates

See more
  • Citius Pharmaceuticals Expands Management Team with Appointment of Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls

    CRANFORD, N.J., Nov. 5, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced the appointment of pharmaceutical industry veteran Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls (CMC). Mr. Creighton will be responsible for the global strategic regulatory and manufacturing development plans for Citius's five pipeline programs. "With two late P

    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Citius Pharmaceuticals, Inc. Announces Appointment of Ilanit Allen as Vice President, Corporate Communications and Investor Relations

    CRANFORD, N.J., May 17, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR) today announced that Ilanit Allen has been appointed Vice President of Corporate Communications and Investor Relations, effective immediately.  In this newly created role, Ms. Allen will spearhead financial communication and investor activities, reporting to Myron Holubiak, President and Chief Executive Officer of Citius. "We are thrilled to welcome Ilanit to the Citius team as we advance our pipeline of first-in-class critical care products," stated Mr. Holubiak. "I am confident that Ilanit's extensive communications and investor relations experience, coupled with her financia

    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CTXR
Financials

Live finance-specific insights

See more
  • Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

    Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024. Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIR™ (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL);Advanced ma

    $CTOR
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments

    Management call scheduled for Tuesday, August 13, 2024, at 8:30 AM ET CRANFORD, N.J., Aug. 12, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), today announced that it will host an investor call on Tuesday, August 13, 2024 at 8:30 am ET to discuss recent and upcoming developments. Citius Chairman and CEO, Leonard Mazur, will be joined by members of the management team. A question and answer period will follow management's discussion. Conference Call Details: Date: Tuesday, August 13, 2024 Time: 8:30 a.m. Eastern Time Dial In: 1-888-243-4451 (U.S. toll free) 1-412-542-4135 (international) Webcast: Register for the webcast here. A replay will

    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

    Management call scheduled for Monday, June 3, 2024 at 8:30 AM ET CRANFORD, N.J., May 29, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it will host an investor call on Monday, June 3, 2024 at 8:30 am ET to discuss the topline results of its Phase 3 Trial of Mino-Lok antibiotic lock solution. Citius Chairman and CEO, Leonard Mazur, will be joined by members of the management team to discuss the results of the Phase 3 Trial and the clinical need for Mino-Lok in patients with catheter-related blood

    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CTXR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more